Clinical and Molecular Hepatology

Original Articles TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD

Baokai Sun, Xiaoqian Ding, Jie Tan, Jie Zhang, Xueru Chu, Shuimi Zhang, Shousheng Liu, Zhenzhen Zhao, Shiying Xuan, Yongning Xin, Likun Zhuang

DOI: 10.3350/cmh.2024.0268 [Epub ahead of print]

Gut microbiome and metabolome signatures in liver cirrhosis-related complications

Satya Priya Sharma, Haripriya Gupta, Goo-Hyun Kwon, Sang Yoon Lee, Seol Hee Song, Jeoung Su Kim, Jeong Ha Park, Min Ju Kim, Dong-Hoon Yang, Hyunjoon Park, Sung-Min Won, Jin-Ju Jeong, Ki-Kwang Oh, Jung A Eom, Kyeong Jin Lee, Sang Jun Yoon, Young Lim Ham, Gwang Ho Baik, Dong Joon Kim, Ki Tae Suk

DOI: 10.3350/cmh.2024.0349 [Epub ahead of print]

Diagnostic accuracy of the Fibrosis-4 index for advanced liver fibrosis in metabolic dysfunction-associated steatotic liver disease with type 2 diabetes: A systematic review and meta-analysis

Ji Won Han, Hee Yeon Kim, Jung Hwan Yu, Mi Na Kim, Young Eun Chon, Ji Hyun An, Young-Joo Jin, Miyoung Choi, Seung Up Kim, Han Ah Lee, Dae Won Jun

DOI: 10.3350/cmh.2024.0330 [Epub ahead of print]

DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease

Amal Magdy, Hee-Jin Kim, Hanyong Go, Jun Min Lee, Hyun Ahm Sohn, Keeok Haam, Hyo-Jung Jung, Jong-Lyul Park, Taekyeong Yoo, Eun-Soo Kwon, Dong Hyeon Lee, Murim Choi, Keon Wook Kang, Won Kim, Mirang Kim

DOI: 10.3350/cmh.2024.0229 [Epub ahead of print]

Erratum Erratum to ‘Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction’ [Clin Mol Hepatol 2024;30:539-560]

Mehrangiz Dezhbord, Seong Ho Kim, Soree Park, Da Rae Lee, Nayeon Kim, Juhee Won, Ah Ram Lee, Dong-Sik Kim, Kyun-Hwan Kim

DOI: 10.3350/cmh.2024.0060e [Epub ahead of print]

Editorials UBE2S: A novel driver of HIF-1alpha-induced metabolic reprogramming in hepatocellular carcinoma

Martina Mang Leng LEI, Terence Kin Wah LEE

DOI: 10.3350/cmh.2024.0568 [Epub ahead of print]

Deep learning Assisted Biomarker Development in Patients with Chronic Hepatitis B

Yong Eun Chung

DOI: 10.3350/cmh.2024.0563 [Epub ahead of print]

Incretin based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle

Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan

DOI: 10.3350/cmh.2024.0558 [Epub ahead of print]

Correspondences Reply to: “Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind”

Xiaoqian Xu, Hong You, Jidong Jia, Yuanyuan Kong

DOI: 10.3350/cmh.2024.0552 [Epub ahead of print]

Original Articles Transient elastography for significant fibrosis in treatment-naïve CHB patients: A systematic review and meta-analysis

Mi Na Kim, Jihyun An, Eun Hwa Kim, Hee Yeon Kim, Han Ah Lee, Jung Hwan Yu, Young-Joo Jin, Young Eun Chon, Seung Up Kim, Dae Won Jun, Ji Won Han, Miyoung Choi

DOI: 10.3350/cmh.2024.0371 [Epub ahead of print]

Genomic Biomarkers to Predict Response to Atezolizumab Plus Bevacizumab Immunotherapy in Hepatocellular Carcinoma: Insights from the IMbrave150 Trial

Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S. Lee, Ahmed O. Kaseb, Young Nyun Park, Sun-Hee Leem, Michael A. Curran, Ji Hoon Kim, Ju-Seog Lee

DOI: 10.3350/cmh.2024.0333 [Epub ahead of print]

Risk Assessment of Hepatitis B virus-related Hepatocellular Carcinoma Development Using Transient Elastography: Systematic Review and Meta-analysis

Young-Joo Jin, Hee Yeon Kim, Miyoung Choi, Seung Up Kim, Young Ju Suh, Chae Hyeon Lee, Jung Hwan Yu, Mi Na Kim, Ji Won Han, Han Ah Lee, Jihyun An, Young Eun Chon, Dae Won Jun

DOI: 10.3350/cmh.2024.0163 [Epub ahead of print]

Editorials Elimination of viral hepatitis: How far are we?

Eun Ju Cho

DOI: 10.3350/cmh.2024.0557 [Epub ahead of print]

Original Articles Non-Linear Association Between Liver Fibrosis Scores and Viral Load in Patients with Chronic Hepatitis B

Gi-Ae Kim, Seung Won Choi, Seungbong Han, Young-Suk Lim

DOI: 10.3350/cmh.2024.0252 [Epub ahead of print]

Replys to Correspondence Reply to correspondence regarding “Class II Transactivator Restricts Viral Replication, Extending its Effect to HBV”

Cho-Rong Lee, Sung-Gyoo Park

DOI: 10.3350/cmh.2024.0572 [Epub ahead of print]

Editorials Reappraisal of Transarterial Radioembolization for Liver-Confined Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

Jin Hyoung Kim, Gun Ha Kim, Dong Il Gwon

DOI: 10.3350/cmh.2024.0516 [Epub ahead of print]

Replys to correspondence Response to: Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era

Seren M. Gedallovich, Paul Y. Kwo

DOI: 10.3350/cmh.2024.0546 [Epub ahead of print]

Review Article Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives

Mengyao Yan, Shuli Man, Long Ma, Lanping Guo, Luqi Huang, Wenyuan Gao

DOI: 10.3350/cmh.2024.0315 [Epub ahead of print]

Original Articles Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)

Chuan Liu, Hong You, Qing-Lei Zeng, Yu Jun Wong, Bingqiong Wang, Ivica Grgurevic, Chenghai Liu, Hyung Joon Yim, Wei Gou, Bingtian Dong, Shenghong Ju, Yanan Guo, Qian Yu, Masashi Hirooka, Hirayuki Enomoto, Amr Shaaban Hanafy, Zhujun Cao, Xiemin Dong, Jing LV, Tae Hyung Kim, Yohei Koizumi, Yoichi Hiasa, Takashi Nishimura, Hiroko Iijima, Chuanjun Xu, Erhei Dai, Xiaoling Lan, Changxiang Lai, Shirong Liu, Fang Wang, Ying Guo, Jiaojian Lv, Liting Zhang, Yuqing Wang, Qing Xie, Chuxiao Shao, Zhensheng Liu, Liu Ravaioli, Antonio Colecchia, Jie Li, Gao-Jun Teng, Xiaolong Qi

DOI: 10.3350/cmh.2024.0198 [Epub ahead of print]

Correspondences Correspondence on Editorial regarding “Class II Transactivator Restricts Viral Replication and Extends Its Effect to HBV”

Mehrangiz Dezhbord, Kyun-Hwan Kim

DOI: 10.3350/cmh.2024.0515 [Epub ahead of print]

Editorials Nucleos(t)ide Analog Therapy of Chronic Hepatitis B and Extrahepatic Cancer Risk: Is tenofovir better than entecavir?

Yewan Park, Dong Hyun Sinn

DOI: 10.3350/cmh.2024.0519 [Epub ahead of print]

Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind

Beom Kyung Kim

DOI: 10.3350/cmh.2024.0499 [Epub ahead of print]

Correspondences The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid's mechanisms of action

Yiyuan Zheng, Zhekun Xiong, Lina Zhao, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Fengbin Liu, Yong Li

DOI: 10.3350/cmh.2024.0471 [Epub ahead of print]

Correspondence on Editorial regarding“Macrophage ATG16L1: potential candidate for MASH treatment”

Qi Wang, Qingfa Bu, Haoming Zhou, Ling Lu

DOI: 10.3350/cmh.2024.0470 [Epub ahead of print]

Letters to the Editor Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease

Yixuan Zhu, Yee Hui Yeo, Xiaoyan Ma, Wenjing Ni, Junping Shi, Jie Li

DOI: 10.3350/cmh.2024.0417 [Epub ahead of print]

Dipeptidyl peptidase-4 inhibitors are associated with improved survival of patients with diabetes mellitus and hepatocellular carcinoma receiving immunotherapy

Dorothy Cheuk-Yan Yiu, Huapeng Lin, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Ken Liu, Terry Cheuk-Fung Yip

DOI: 10.3350/cmh.2024.0280 [Epub ahead of print]

Editorials Class II Transactivator Restricts Viral Replication, Extending its Effect to HBV

Cho-Rong Lee, Sung-Gyoo Park

DOI: 10.3350/cmh.2024.0465 [Epub ahead of print]

Severity of microvascular invasion does matter in hepatocellular carcinoma prognosis

Abdelrahman M Attia, Hasmik Adetyan, Ju Dong Yang

DOI: 10.3350/cmh.2024.0482 [Epub ahead of print]

Correspondences Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era

Chung-Feng Huang, Manar Hijaze Awad, Meital Gal-Tanamy, Ming-Lung Yu

DOI: 10.3350/cmh.2024.0472 [Epub ahead of print]

Special Topic A new Korean nomenclature for steatotic liver disease: Nonalcoholic Fatty Liver Disease (NAFLD) Nomenclature Revision Consensus Task Force on behalf of the Korean Association for the Study of the Liver (KASL)

DOI: 10.3350/cmh.2024.0467 [Epub ahead of print]

Reviews Current status and perspective on molecular targets and therapeutic intervention strategy in hepatic ischemia-reperfusion injury

Jia Liu, Ranyi Luo, Yinhao Zhang, Xiaojiaoyang Li

DOI: 10.3350/cmh.2024.0222 [Epub ahead of print]

Editorials Engineering HBV-specific T cells for treatment of HBV-related HCC and HBV infection: past, present and future

Antonio Bertoletti, Anthony T Tan

DOI: 10.3350/cmh.2024.0469 [Epub ahead of print]

Reviews Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip

DOI: 10.3350/cmh.2024.0246 [Epub ahead of print]

Original Articles UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL

Renyu Zhang, Can Li, Shuai Zhang, Lingmin Kong, Zekun Liu, Yixiao Guo, Ying Sun, Cong Zhang, Yule Yong, Jianjun Lv, Meng Lu, Man Liu, Dong Wu, Tianjiao Zhang, Haijiao Yang, Ding Wei, Zhinan Chen, Huijie Bian

DOI: 10.3350/cmh.2024.0236 [Epub ahead of print]

Burden of Mortality from Hepatocellular Carcinoma and Biliary Tract Cancers by Race and Ethnicity and Sex in US, 2018-2023

Donghee Kim, Richie Manikat, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed

DOI: 10.3350/cmh.2024.0318 [Epub ahead of print]

Correspondences Correspondence on Editorial regarding “Dynamic Assessment of Modified Quick Sequential Organ Failure Assessment in Acutely Deteriorated Patients with Chronic Liver Disease”

Do Seon Song, Dong Joon Kim

DOI: 10.3350/cmh.2024.0448 [Epub ahead of print]

Editorials Macrophage ATG16L1: potential candidate for MASH treatment

Junjie Yu

DOI: 10.3350/cmh.2024.0443 [Epub ahead of print]

Letters to the Editor MAFLD-related hepatocellular carcinoma in China: An increasing problem

Xiangyu Wu, Wenjing Ni, Qianqian Chen, Junping Shi, Jie Li

DOI: 10.3350/cmh.2024.0386 [Epub ahead of print]

Editorials The impact of ischemia-free liver transplantation to improve the prognosis of recipients using functionally marginal liver grafts

Ho Joong Choi

DOI: 10.3350/cmh.2024.0426 [Epub ahead of print]

Metformin and Statins and their role in reducing Hepatocellular Carcinoma Risk: Randomized trials are needed

Paul Y. Kwo

DOI: 10.3350/cmh.2024.0425 [Epub ahead of print]

Meeting the challenges of HCC post SVR in the Post-DAA Era: A Path Forward

Seren M. Gedallovich, Paul Y. Kwo

DOI: 10.3350/cmh.2024.0418 [Epub ahead of print]

Ursolic acid: A promising therapeutic agent for MASLD via inhibition of SPP1-induced Th17 cell differentiation

So Jung Kim, Jeongeun Hyun

DOI: 10.3350/cmh.2024.0412 [Epub ahead of print]

Modified quick-SOFA score: can it enhance prognostic assessment for hospitalized patients with chronic liver diseases?

Simone Incicco, Salvatore Piano

DOI: 10.3350/cmh.2024.0409 [Epub ahead of print]

Correspondences Correspondence on editorial regarding “Atezolizumab and bevacizumab for hepatocellular carcinoma: how to approach salvage therapy for non-responders?”

Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim

DOI: 10.3350/cmh.2024.0394 [Epub ahead of print]

Original Articles Genetically redirected HBV-specific T cells target HBsAg-positive hepatocytes and primary lesions in HBV-associated HCC

Xueshuai Wan, Karin Wisskirchen, Tao Jin, Lu Yang, Xiaorui Wang, Xiang’an Wu, Fang Liu, Yu Wu, Christy Ma, Yong Pang, Qi Li, Ke Zhang, Ulrike Protzer, Shunda Du

DOI: 10.3350/cmh.2024.0058 [Epub ahead of print]

Editorials MAFLD Is A Ubiquitous Latent Cofactor in Viral- and Alcoholic-related Hepatocellular Carcinoma

Toru Nakamura, Masahito Nakano, Tsubasa Tsutsumi, Keisuke Amano, Takumi Kawaguchi

DOI: 10.3350/cmh.2024.0372 [Epub ahead of print]

Correspondences Correspondence on Editorial regarding “Unveiling etiology-specific blood biomarkers in hepatocellular carcinoma: a gateway to personalized medicine”

Su Bin Lim, Hyo Jung Cho

DOI: 10.3350/cmh.2024.0368 [Epub ahead of print]

Reply to Unlocking the future: machine learning sheds light on prognostication for early-stage hepatocellular carcinoma

Chun-Ting Ho, Elise Chia-Hui Tan, Chien-Wei Su

DOI: 10.3350/cmh.2024.0365 [Epub ahead of print]

Replys to Correspondence Reply to correspondence: “Prognosis of biopsy-confirmed MASLD: A sub-analysis of the CLIONE study”

Eileen Laurel Yoon, Dae Won Jun